The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound ...

阻塞性睡眠呼吸暂停是一种常见的睡眠障碍，主要表现为在睡眠过程中反复出现呼吸暂停。这种疾病在30至69岁的人群中尤为普遍，全球估计有4.25亿人患有中度至重度OSA。仅在中国，患者人数就高达1.76亿，形势可谓严峻。OSA不仅影响患者的睡眠质量，还会引发一系列健康问题。研究表明，OSA患者发生中风的概率是普通人的4.33倍，病死率则是普通人的1.98倍。

The FDA declared that shortages of tirzepatide and semaglutide had ended when the drug manufacturers’ “stated product availability and manufacturing capacity can meet the present and ...

The FDA officially deemed the nearly two-year shortage of tirzepatide resolved earlier this month.. Days later, the Outsourcing Facilities Association, a trade group representing large-scale ...

If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...

The FDA has issued warning letters to two companies for offering unapproved and misbranded versions of semaglutide and tirzepatide on their websites, according to a press release. On Feb. 7, the ...

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity Published. Dec 20, 2024 4:32pm EST ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

The FDA announced it approved the injectable dual incretin agonist tirzepatide to improve glucose response in adults with type 2 diabetes in addition to diet and exercise.Tirzepatide (Mounjaro ...